Biopharma

Abstract To facilitate the development of protein depots for sustained delivery, this study optimized spray-dried formulations of a model antibody...

Abstract Inhaled biologics to treat lung diseases have an extensive history. This is counterbalanced by the limited products that have...

Abstract 3D printing has emerged as a novel technology for producing personalized dosage forms tailored to patients’ therapeutic needs. Hot-melt...

Focused on your needs – BASF solutions for the pharmaceutical industry BASF produces excipients and active ingredients of outstanding quality...

Capsugel®/ Lonza published a new podcast episode: For years, oral delivery of biologics has been viewed as impractical. But what...

Abstract Oxidation represents a key pathway for the chemical degradation of therapeutic monoclonal antibodies (mAbs), and chemical liabilities such as...

Biopharmaceutical excipients are the inactive substances added to biologic drug products to protect large, structurally fragile biomolecules, such as monoclonal...

GELITA has launched an ultra low endotoxin gelatin, specified at less than 10 endotoxin units (EU) per gram, for sensitive...

Messenger RNA (mRNA) is intrinsically unstable due to spontaneous 2'-hydroxyl-mediated phosphodiester hydrolysis, with degradation rates accelerating at pH below 5.0...

Abstract There is a growing demand in the subcutaneous delivery of monoclonal antibodies (mAbs) to reduce treatment burden for both...